Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04574856 · ClinicalTrials.gov registry record · Phase 2
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by University of Michigan Rogel Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04574856: Active Phase 2 study of Glioblastoma, sponsored by University of Michigan Rogel Cancer Center.
NCT04574856 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 30 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04574856, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
Primary Outcome
12-month overall survival rate of study participants (failure defined as death due to any cause)
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Dose-Intensified Radiotherapy
- DRUG Adjuvant temozolomide
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT04574856 still lists
NCT04574856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT04574856 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04574856 about?
NCT04574856 is a clinical study titled "Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma". This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
What is the current status of trial NCT04574856?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-11-04. Estimated completion is 2026-10.
What conditions does trial NCT04574856 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04574856?
The interventions under investigation include: Temozolomide (DRUG), Dose-Intensified Radiotherapy (RADIATION), Adjuvant temozolomide (DRUG).
Who is sponsoring clinical trial NCT04574856?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04574856 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04574856's enrollment target sits among peer trials
30 124th of 199 higher than 69 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI